🔎 Trials Near Me

Home › Ovarian Cancer › New Mexico

Ovarian Cancer clinical trials in New Mexico

16 studies for Ovarian Cancer are looking for participants at sites in New Mexico.

Cities in New Mexico

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • University of New Mexico Cancer Center, Albuquerque
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377

DESTINY-PANTUMOUR04

  • Research Site, Farmington
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  • Research Site, Albuquerque
RecruitingPhase 2
Ages 18 to 130 · All sexes · Updated Sep 23, 2026 · NCT05489211

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • Optimum Clinical Research Group, Albuquerque
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213804

Prospective Laboratory Study Biologic Specimens and Tumor Tissue of Patients With Cancer

  • University of New Mexico Cancer Center, Albuquerque
RecruitingObservational study
Ages 18 and older · Women · Updated Sep 18, 2026 · NCT03943316

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Unm Comprehensive Cancer Center, Albuquerque
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 15, 2026 · NCT07214779

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

  • Research Site, Albuquerque
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT05123482

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  • University of New Mexico Comprehensive Cancer Center ( Site 0055), Albuquerque
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06824467

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  • University of New Mexico Cancer Center, Albuquerque
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07001748

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  • University of New Mexico Cancer Center, Albuquerque
  • Presbyterian Rust Medical Center/Jorgensen Cancer Center, Rio Rancho
Recruiting
Ages 35 to 50 · Women · Updated Aug 7, 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  • University of New Mexico Cancer Center, Albuquerque
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06580314

Clinical Pre-screening Protocol for Ovarian Cancer

  • University of New Mexico Comprehensive Cancer, Albuquerque
RecruitingObservational study
Ages 18 and older · Women · Updated Jul 30, 2026 · NCT03877796

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

  • 292, Albuquerque
RecruitingPhase 2
Ages 18 and older · Women · Updated Jul 16, 2026 · NCT06906341

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

  • University of New Mexico Comprehensive Cancer Center, Albuquerque
RecruitingPhase 3
Ages 18 and older · Women · Updated Apr 16, 2026 · NCT05659381

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Albuquerque
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.